Safety Study of SGN-CD70A in Cancer Patients

• Status: Completed
• Trial end date: 2017-02-15
• Target enrollment: 0
• Participant gender: All

Summary

This study will examine the safety profile of SGN-CD70A. The study will test increasing doses of SGN-CD70A given every 3 weeks (or an alternate dosing schedule up to every 6 weeks) to small groups of patients. The goal is to find the highest dose of SGN-CD70A that can be given to patients without causing unacceptable side effects. The pharmacokinetics and antitumor activity of SGN-CD70A will also be evaluated.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seagen Inc.; Seattle Genetics, Inc.

Criteria

Inclusion Criteria:

• Metastatic renal cell carcinoma, mantle cell lymphoma, or diffuse large B-cell lymphoma including Grade 3b follicular lymphoma

• Relapsed, refractory, or progressive disease following at least 2 prior systemic therapies

• Confirmed positive CD70 expression on tumor tissue

• Eastern Cooperative Oncology Group performance status 0 or 1

• Adequate baseline hematologic, pulmonary, renal, and hepatic function

• Measurable disease

Exclusion Criteria:

• Prior treatment with anti-CD70 directed therapy unless CD70 expression is confirmed on tumor tissue obtained after the treatment

• Patients <100 days since prior allogeneic stem cell transplant

• Less than 4 weeks since prior treatment; or 2 weeks if patient experienced disease progression on the prior treatment